GSK/Ivannova study Relvar/Breo once-daily cobination

GlaxoSmithKline and Innoviva have started a phase III study to compare certain triple combination asthma therapy with a double combination therapy with Relvar/Breo.

The study will consider once-daily triple fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with once-daily dual combination therapy.

The closed triple combination study therapy will be delivered once-daily in GSK’s Ellipta dry powder inhaler. 

The company believes that receiving dual bronchodilators with inhaled steroid once a day with single ingalation will benefit more than triple therapy in two or more inhalers.

Dave Allen, Head of Respiratory R&D at GSK, said, “Despite the availability of treatments, many patients have asthma that is inadequately controlled.“ 

Mike Aguiar, CEO of Innoviva, Inc., added, ” If successful, this would further expand the portfolio of respiratory therapy products delivered via the Ellipta inhaler for the treatment of asthma and COPD.”